REPLIMUNE GROUP, INC. Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
REPLIMUNE GROUP, INC. (REPL) had Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss of $346.32 million as of 2024-03-31, per its 10-K filed 2024-05-16.
Discontinued › Balance Sheet › Assets
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss · last filed 2024-05-16
- 2024-03-31: Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss $346.32M.
- 2023-03-31: Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss $436.86M.
| Period end | Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss |
|---|---|
| 2024-03-31 | $346.32M 10-K · filed 2024-05-16 |
| 2023-03-31 | $436.86M 10-K · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |